Related Experiment Video

Updated: Jul 13, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients

Madiha Mahmoud1, Rania Abdel-Kader, Moataz Hassanein

  • 1Pharmacology Department, Theodor Bilharz Research Institute, Egypt.

European Journal of Pharmacology
|July 14, 2007
PubMed

Insights

Antipyrine clearance measured in saliva is a sensitive marker for liver function in hepatitis C patients. This test effectively identifies even minimal hepatic impairment, correlating well with liver disease severity.

Area of Science:

  • Hepatology
  • Pharmacokinetics
  • Biomarker Discovery

Background:

  • Hepatitis C virus (HCV) infection leads to liver cirrhosis, necessitating accurate assessment of liver function.
  • Conventional liver function tests (LFTs) have limitations in detecting early-stage hepatic impairment.

Purpose of the Study:

  • To evaluate antipyrine clearance, measured in saliva, as a sensitive biomarker for liver function in patients with HCV.
  • To compare the efficacy of antipyrine clearance with conventional LFTs and Child-Pugh scores in assessing hepatic function.

Main Methods:

  • 15 healthy volunteers and 96 HCV patients (Child-A, B, C) ingested 600 mg antipyrine.
  • Saliva samples were collected at 4 and 24 hours post-ingestion for high-performance liquid chromatography analysis.
  • Conventional LFTs and Child-Pugh scores were assessed concurrently.

Main Results:

  • Antipyrine clearance was significantly reduced in all Child-Pugh groups (A, B, C) compared to healthy volunteers.
  • Saliva-based antipyrine clearance demonstrated a strong negative correlation with Child-Pugh scores and other established markers.
  • Antipyrine clearance proved sensitive in detecting impairment even in Child-A patients, indicating minimal hepatic dysfunction.

Conclusions:

  • Saliva-based antipyrine clearance is a sensitive, non-invasive biomarker for assessing liver function in HCV patients.
  • This method effectively identifies minimal hepatic impairment, offering an advantage over some conventional LFTs.
  • Antipyrine clearance provides valuable insights into the liver's intrinsic clearance capacity, aiding in disease management.

More Related Videos

Stabilizing Hepatocellular Phenotype Using Optimized Synthetic Surfaces08:50

Stabilizing Hepatocellular Phenotype Using Optimized Synthetic Surfaces

Published on: September 26, 2014

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...